Ali Ghulam and colleagues report in Genomics & Informatics that a capsule neural network beat CNN and LSTM baselines using dipeptide composition features.
Recap by typeshit. Full story at BIOENGINEER.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
Loading…